Corporate Banner
Satellite Banner
Technology Networks Header
Saturday, December 20, 2014
Technology Networks
 
Register | Sign in
Home Page > Latest Webcasts
  Webcasts
Scientific News
Novel Agent Decreases Neuropathic Pain in Patients with Type 2 Diabetes
Promising profile of disease modification and pain reduction leads to proof of concept trials.
Barrier-Breaking Drug May Lead to Spinal Cord Injury Treatments
NIH-funded scientists take first step towards developing promising new drug.
Two Drugs are No More Effective Than One to Treat Common Kidney Disease
NIH study finds limited kidney benefit from more rigorous blood pressure treatment.
Antibiotic Resistance Threatens Future of Modern Medicine
Overuse and misuse of antibiotics, one of the key contributors to antimicrobial resistance (AMR).
Computer Model Sets New Precedent in Drug Discovery
New computational model can precisely simulate, predict therapeutic protein behaviors to help zero in on ideal drug design candidates.
New Drug for Common Liver Disease Improves Liver Health
An experimental drug aimed at treating a common liver disease showed promising results and potential problems in a multicenter clinical trial funded by the NIH.
'Rewriting' the Way to Make Natural Drug Compounds
Using an organism's own pathway to synthesize potential therapeutics.
MS Drug Candidate Shows Promise for Ulcerative Colitis
Positive new clinical data were released today on a drug candidate for ulcerative colitis that was first discovered and synthesized at The Scripps Research Institute.
New Technique has Profound Implications for Drug Development
The method, developed by Scripps Research Institute chemists, expands options for making pure batches of ‘one-handed’ molecules.
Team Discovers How Microbes Build a Powerful Antibiotic
Researchers discovery opens up new avenues of research into thousands of similar molecules.
Scroll Up
Scroll Down
Return
Latent Hit Identification in Primary Screening Data with Compound Set Enrichment
Thibault Varin, PostDoctoral Fellow, Novartis, Speaking at Medchem Europe 2011.
Date Posted: Thursday, December 01, 2011
Print Page

For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here



Novartis Provides Drug Candidate Compounds to TB Alliance
Exclusive worldwide license from Novartis includes a novel class of drugs that is active against drug sensitive and multi-resistant strains of tuberculosis.
Wednesday, August 20, 2014
Novartis Announces Portfolio Transformation
Company launches a major overhaul of its business, unveiling a series of multibillion-dollar deals with GSK and Eli Lilly.
Wednesday, April 23, 2014
Novartis and Collaborators Discover Novel Antimalarial Drug Candidate
New antimalarial drug candidate with novel mechanism of action has the potential to rapidly clear a Plasmodium infection upon administration of a single oral dose, as published in Science.
Tuesday, September 07, 2010
Novartis Gains Rights to Two Oral Targeted Investigational Therapies
Ex-US rights acquired for JAK inhibitor INCB18424 in Phase III development as first-in-class treatment for a life-threatening blood disorder.
Tuesday, December 01, 2009
Nuevolution Announces New Research Collaboration with Big Pharma
Partnership to use Nuevolution's Chemetics® technology for lead discovery.
Tuesday, September 01, 2009
Novartis Begins Shipment of Fluvirin® Seasonal Influenza Vaccine for U.S. Market Ahead of Schedule
Company is providing 30 million doses of Fluvirin vaccine to support the annual seasonal influenza vaccination campaign.
Thursday, August 06, 2009
FORMA Announces Collaboration with Novartis to Develop Inhibitors of Protein-Protein Interactions
FORMA will leverage its expertise to develop inhibitors for an undisclosed protein-protein interaction target in the field of oncology.
Tuesday, January 13, 2009
Dynavax Enters Into Supply and Option Agreement for Development of Universal Influenza Vaccine
Novartis will provide Dynavax a supply of trivalent influenza vaccine for both clinical trial use and vaccine sales.
Thursday, July 24, 2008
 
Skyscraper Banner
SELECTBIO Market Reports
LabTube - Videos for the Scientific Community
eposters - The Online Journal of Scientific Posters
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn